Wegovy (Semaglutide) for
Weight Loss in India
A plain-language educational guide to Wegovy — what it is, how it works for weight loss, its approved use, who may be a candidate, and why it must be used under medical supervision. Medically reviewed by Dr. Manuj Sondhi, MRCP (UK), MD, DNB — Consultant Physician & Diabetologist, Nirvana Clinic, Greater Noida · Last updated: 10 July 2026Part of the complete GLP-1 Therapy Guide for India → This page is for information only; it is not advice, advertising, or an offer to supply any medicine.
Wegovy (Semaglutide 2.4 mg) — How It Works
Wegovy is a once-weekly injectable medicine by Novo Nordisk containing semaglutide. In India it is approved by the Central Drugs Standard Control Organisation (CDSCO) for chronic weight management, and it has been available in India since 2025. This page is part of our complete GLP-1 therapy guide for India.
Wegovy is a GLP-1 receptor agonist — it mimics a natural gut hormone that signals fullness to the brain, slows stomach emptying, and improves insulin sensitivity. Combined with nutrition and activity, this can reduce appetite and support sustained, medically supervised weight loss.
Semaglutide also has two clinically notable features for the right patients: it has cardiovascular outcome data from a large trial programme (SELECT), and it is being studied in fatty-liver disease (MASH). These are general points of evidence, not a promise of any individual result.
In India, Wegovy is prescribed for adults with BMI ≥30 (obesity), or BMI ≥27 with a weight-related condition such as type-2 diabetes, hypertension, high cholesterol, fatty liver, or PCOS. It is prescription-only and must be used under medical supervision.
"For many patients, semaglutide at the right maintenance dose is a sensible balance of effectiveness and a well-characterised safety and evidence base. But it is a tool that works only with proper patient selection, careful dosing, and monitoring — alongside nutrition and activity. It is not for everyone, and it is not a shortcut."— Dr. Manuj Sondhi, MRCP (UK), Consultant Physician & Diabetologist, Nirvana Clinic, Greater Noida
Semaglutide vs Tirzepatide — How They Differ
A factual comparison of the two molecules. This is general education, not a recommendation of one medicine over another; suitability is decided individually with a physician.
(Semaglutide)
(Tirzepatide)
Effects described qualitatively; trial averages vary between individuals. Both are prescription-only. Read the fuller educational comparison: Semaglutide vs Tirzepatide →
Who May — and May Not — Be a Candidate
General guidance only. Whether Wegovy is appropriate for a particular person can only be decided by a physician after individual assessment.
How Supervised Treatment Works at Nirvana Clinic
A medically supervised programme — not a prescribe-and-send-away service. Where treatment is appropriate, Dr. Manuj monitors progress at every step.
Consultant Physician & Diabetologist — Nirvana Clinic & Fortis Hospital, Greater Noida
An MRCP (UK)-qualified physician and diabetologist with 15+ years in metabolic medicine, Dr. Manuj has applied that experience to GLP-1 therapy since its India launch. His focus is the underlying metabolic picture behind obesity — not just the number on a scale — with a thorough, evidence-based approach to patient selection, dosing, and monitoring.
Wegovy in India — Frequently Asked Questions
QWhat is Wegovy approved for in India?▼
Wegovy (semaglutide 2.4 mg) is approved in India for chronic weight management in adults with obesity, or with overweight plus a weight-related condition. It is a once-weekly injectable, prescription-only medicine that must be used under medical supervision.
QHow does Wegovy work?▼
Wegovy is a GLP-1 receptor agonist. It mimics a natural gut hormone that signals fullness, slows stomach emptying, and improves insulin sensitivity — which can reduce appetite and support weight loss with nutrition and activity. Semaglutide also has cardiovascular outcome data (SELECT) and is being studied in fatty-liver disease (MASH).
QHow does Wegovy differ from tirzepatide (Mounjaro)?▼
Wegovy contains semaglutide and acts on the GLP-1 receptor; Mounjaro contains tirzepatide and acts on two receptors (GIP and GLP-1). Trials suggest tirzepatide produces a greater average weight reduction, while semaglutide has established cardiovascular outcome data. The right choice for an individual is decided with a physician.
QWhat does Wegovy cost in India?▼
Cost varies by brand, dose, pharmacy and over time, and is discussed only after medical assessment where treatment is clinically appropriate. For current pricing, ask your physician or a licensed pharmacy. This page does not provide drug prices.
QWho should not take Wegovy?▼
It is not suitable for people with type-1 diabetes, a personal or family history of medullary thyroid carcinoma or MEN-2, a history of pancreatitis or severe gastrointestinal disease, an eating disorder, or during pregnancy or planned conception. A physician assessment is essential.
QHow do I arrange a supervised assessment in Greater Noida?▼
Call or WhatsApp Dr. Manuj Sondhi at +91 8800262767. Nirvana Clinic, Shop GF-93, Sun Twilight Mall, opposite Delta 1 Metro Station, Greater Noida. A full consultation with blood tests is required before any treatment. Mon–Sat, 9 AM to 8 PM.
Considering Medically Supervised Weight Loss?
Whether a medicine like semaglutide is appropriate for you can only be decided after a proper evaluation.
Supervised assessment with Dr. Manuj Sondhi, MRCP (UK) · Mon–Sat, 9 AM–8 PM
Last updated: 10 July 2026